Highlights

  • Substantial cost reductions, with all employee positions made redundant.
  • $1.694 million R&D tax incentive refund received on 7 October 2026.
  • Fully underwritten entitlement offer to raise about $913,000 announced.
  • Board evaluating development pathways and strategic options for Cymerus.

Cynata Therapeutics Limited (ASX:CYP) has released its quarterly activity report and Appendix 4C for the period ended 30 September 2026. The quarter followed the release of results from its Phase 2 aGvHD trial and CYP-004 osteoarthritis trial in June 2026, after which the company made major changes to its cost base and structure.

Cost Reductions and Board Changes

On 6 July 2026, Cynata substantially reduced expenditure. All employee positions, including the CEO and Managing Director role, were made redundant, and the Board now manages the company. Former CEO Dr Kilian Kelly remains as a Non-Executive Director, while Dr Darryl Maher resigned as a Director.

Service agreements for the Phase 2 aGvHD trial were terminated, and other outsourced activities were suspended or ended where possible, while preserving the company's intellectual property. After the quarter, Dr Paul Wotton announced he will step down at the AGM on 25 November 2026.

Cash Position and Funding

Cash at quarter end was $175,000, after a net operating outflow of $1.316 million that included several one-off payments. On 7 October 2026, Cynata received a $1.694 million R&D tax incentive refund and fully repaid a $600,000 short-term loan, leaving net proceeds of $1.067 million.

The company also announced a three-for-eight fully underwritten renounceable entitlement offer to raise about $913,000 before costs, and terminated its at-the-market facility with Acuity Capital. Cynata expects its cash runway to extend into the 2028 financial year.

Future of the Cymerus Platform

Cynata's core asset is its Cymerus platform, a method for manufacturing mesenchymal stromal cells at commercial scale from a single cell source.

The Board is evaluating future development pathways for the technology and is also considering broader strategic options, including realising value from Cymerus and acquiring rights to new assets.

Key Takeaways

  • Cynata has sharply reduced costs and moved to a board-managed structure.
  • The R&D tax refund and entitlement offer support its funding position.
  • The company expects its cash runway to extend into FY2028.
  • Strategic options for the Cymerus platform are under review.